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Abstract: The ubiquitin–proteasome system has become a promising molecular target in cancer 
therapy due to its critical role in cellular protein degradation, interaction with cell cycle and 
apoptosis regulation, and unique mechanism of action. Bortezomib (PS-341) is a potent and 
specific reversible proteasome inhibitor, which has shown strong in vitro antitumor activity as 
single agent and in combination with other cytotoxic drugs in a broad spectrum of hematologi-
cal and solid malignancies. In preclinical studies, bortezomib induced apoptosis of malignant 
cells through the inhibition of NF-κB and stabilization of pro-apoptotic proteins. Bortezomib 
also promotes chemo- and radiosensitization of malignant cells in vitro and inhibits tumor 
growth in murine xenograft models. The proteasome has been established as a relevant target 
in hematologic malignancies and bortezomib has been approved for the treatment of multiple 
myeloma. This review summarizes recent data from clinical trials in solid tumors.
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Introduction
Proteasome inhibitors represent a class of drugs that have anticancer activity through 
a variety of cellular mechanisms including induction of apoptosis, interference 
with cell cycle progression, inhibition of angiogenesis, and suppression of nuclear 
transcription factor kappa B (NF-κB).1 The proteasome is a multicatalytic enzyme 
complex that degrades several intracellular proteins by a targeted and controlled 
mechanism.2–4 The activity of proteasome in degradation of tumor-suppressing and 
proapoptotic protein targets known to be dysregulated in many human malignancies 
provides the rationale for its selection as a target for cancer therapy. The first-in-class 
proteasome inhibitor, bortezomib (PS-341; Velcade®; Millennium Pharmaceuticals), 
a boronic acid dipeptide derivative, received approval in the United States (2003) 
and Europe (2004) for relapsed and refractory multiple myeloma.5–7 In the APEX 
phase III study, comparing bortezomib and dexamethasone in patients with multiple 
myeloma, the median time to progression was significantly increased from 106 days 
with dexamethasone to 189 days with bortezomib and the 1-year overall survival 
was also higher in the bortezomib arm (80% vs 66%).7 Recently, the FDA approved 
bortezomib in relapsed mantle cell lymphoma.8
Bortezomib has also shown activity in preclinical studies of a variety of 
solid tumors, and this has paved the way for several phase I/II clinical studies of 
bortezomib either as single agent or in combination with cytotoxic and biologic 
agents.OncoTargets and Therapy 2009:2 172
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This review aims to highlight current knowledge of the 
anticancer effects of bortezomib with emphasis on recent 
clinical studies.
Mechanism of action of proteasome
The ubiquitin-mediated proteasome pathway regulates 
a group of intracellular proteins that govern cell cycle, 
tumor growth, and survival. Proteasome participates 
in the turnover and degradation of several pathways, 
or short-lived cellular regulatory proteins, including 
p53, cyclins and the cyclin-dependent kinase (CDK) 
inhibitors p21 and p27, the estrogen receptor, and the 
inhibitor (IκB) of NF-κ.9–13 26S proteasome consists 
of a multisubunit, cylindrical complex including a 20S 
core catalytic component and 19S regulatory particles 
that contain polyubiquitin-binding sites and isopeptidase 
activity for the cleavage and release of ubiquitin from the 
protein substrate.14 The proteasome requires adenosine 
triphosphate (ATP) hydrolysis and regulates multicata-
lytic protease that selectively degrades polyubiquinated 
proteins. These proteins get marked for degradation by a 
multistep process. Prior to degradation, polyubiquitinated 
moieties are covalently attached to the target proteins in 
a multistep process involving three distinct enzymes: 
the ubiquitin-activating enzyme E1 binds ubiquitin and 
transfers it to the ubiquitin-conjugating enzyme E2. In the 
following step the ubiquitin ligase E3 catalyzes the transfer 
of the polyubiquitinated tails from E2 to lysine residues 
of the target protein, specifically marking them for prote-
olysis protein into small fragments in an ATP-dependent 
manner.4,15 Activated p53 arrests cells in the G1-phase 
and promotes apoptosis to allow elimination of damaged 
cells through induction of the proapoptotic protein Bax, 
which, in turn, is also a proteasomal substrate. The final 
outcome of this process is proteasome inhibitor-induced 
stabilization of p53, p21Cip1, p27Kip1, and Bax, dysregulation 
of cell-cycle progression and, finally, apoptosis.16
The proteasome modulates also the activity of the 
transcription factor nuclear NF-κB. The NF-κB pathway 
is activated by a variety of cellular stress signals, and 
chemo- and radiotherapy, which lead to phosphorylation of 
a serine residue on IκB, which targets it for ubiquitination 
and proteasomal degradation. This process allows activated 
the NF-κB subunit to translocate into the nucleus, where 
it induces expression of a variety of genes encoding 
cell adhesion molecules and antiapoptotic factors 
(Figure 1).17–19 More details have been provided in our 
previous review.20
Preclinical studies of proteasome 
inhibitors
Proteasome inhibitors have been shown to be cytotoxic against 
a variety of cancer cell lines in vitro and in in vivo models. 
The activity of bortezomib in solid tumors in vivo has been 
evaluated in a variety of xenograft models.21,22
Bortezomib also increases the sensitivity of tumor cells 
to chemotherapy and radiation and reverses chemoresistance. 
Bortezomib was two times more potent in inhibiting the growth 
of chemoresistant multiple myeloma cells compared with che-
mosensitive cells, in direct correlation with NF-κB activity.23 
In colon carcinoma cells, bortezomib inhibited the radiation-
induced increase in NF-κB and enhanced radiosensitivity.24
Many chemotherapeutics induce NF-κB and thereby 
activate an antiapoptotic program that, if inhibited, can 
enhance the antitumor activity of the chemotherapeutic.25 Inhi-
bition of the proteasome was shown initially to increase the 
efficacy of CPT-11 (irinotecan) through blockade of NF-κB 
in a model of colon cancer.26 In another study, gemcitabine 
caused a 59% reduction of pancreatic cancer volume 
compared with control, while the combination of gemcitabine 
and bortezomib increased growth inhibition to 75%.27
Taken together, results from preclinical studies show that 
bortezomib can induce apoptosis in a number of otherwise 
resistant tumor cells and can sensitize cancer cells to other 
cytotoxic agents and radiation therapy.
Clinical studies
The clinical feasibility of using bortezomib for treating solid 
malignancies has been explored in a number of phase I and II 
studies, the main of which are summarized below.
Phase i studies
A number of phase I trials have been carried out with different 
schedules of bortezomib.
A phase I clinical study evaluated the dose-limiting 
toxicity (DLT) and maximum-tolerated dose (MTD) of 
bortezomib as single agent administered as an intravenous 
bolus once-weekly for 4 out of 5 weeks in 53 patients, 
48 of whom had advanced androgen-independent prostate 
cancer. The DLT was seen in 2 of 5 patients treated with 
a dose of 2.0 mg/m2, and it included grade 3 diarrhea in 
both patients and grade 3 syncope and hypotension in one 
patient; so, the recommended phase II dose of bortezomib 
was 1.6 mg/m2. Two patients with prostate cancer had 
prostate-specific antigen response, whereas 2 patients had 
partial response in lymph nodes. The biologic activity, 
such as inhibition of NF-κB related markers, was seen OncoTargets and Therapy 2009:2 173
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at tolerated doses of bortezomib. The maximum level of 
20S inhibition was 70% to 75%, which suggests that the 
inhibition of proteasome is saturable.28 Another phase I 
study tested two different schedules (schedule 1: twice 
weekly for 4 out 6 weeks; schedule 2: twice weekly for 2 out 
of 3 weeks) of bortezomib in 44 patients with advanced 
cancers. The most common toxicity was thrombocytopenia, 
which was dose limiting at 1.7 mg/m2 (schedule 1) and 
1.6 mg/m2 (schedule 2), whereas the MTD was 1.5 mg/m2 
for both schedules. A patient with multiple myeloma had a 
partial response.29 Another schedule of bortezomib (starting 
dose: 1.0 mg/m2 on days 1, 4, 8, 11, every 3 weeks) was 
tested in a phase I/II study in 18 patients with unresectable 
hepatocellular carcinoma. Grade 2/3 toxicities included 
thrombocytopenia, fatigue, and neuropathy. MTD was con-
sidered to be 1.3 mg/m2. In 7/15 evaluable patients, stable 
disease was observed.30 The phase I single-agent studies 
with bortezomib are summarized in Table 1.
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Figure 1 Several intra- and extracellular factors induce the intracellular increase of the iKK complex which phosphorylates the iKB protein. Phosphorylation of iKB causes its 
ubiquitination and degradation by 26S proteasome. NF-κB complex is then able to interact with its DNA ligand site, stimulating transcription of several genes which prompt 
apoptosis inhibition, growth factor increases, and cell survival. Bortezomib acts by inhibiting 26S proteasome.
Abbreviation: rOS, reactive oxygen species.
Table 1 Phase i single agent studies of bortezomib
Patient population Prostate cancer Advanced others solid tumors Hepatocarcinoma
Number of patients 53 46 14
Schedule Starting dose of 0.13 mg/m2 
iv once weekly for 4 weeks 
q5 weeks
Arm 1: starting dose of 0.13 mg/m2 
iv twice weekly for 4 weeks q6 weeks 
Arm 2: starting dose of 0.13 mg/m2  
iv twice weekly for 2 weeks q3 weeks
Starting dose of 1.0 mg/m2 
iv on days 1, 4, 8, 11 q3 weeks
Best response obtained 2 Pr 2 SD 1 Pr 7 SD
Toxicity observed Diarrhea and hypotension Neurotoxicity and fatigue Thrombocytopenia, 
neurotoxicity and fatigue
MTD 1.6 mg/m2 Arm 1: 1.7 mg/m2 Arm 2: 1,6 mg/m2 1.3 mg/m2
Abbreviations: Pr, partial response; SD, stable disease; MTD, maximum-tolerated dose.OncoTargets and Therapy 2009:2 174
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Following preclinical studies which highlighted the 
synergy between bortezomib and taxanes,31,32 a phase I 
trial of twice-weekly bortezomib and weekly docetaxel 
was carried out; the recommended doses were 0.8 mg/m2 
and 25 mg/m2, respectively, every 21 days. The DLT were 
thrombocytopenia and febrile neutropenia. Clinical activ-
ity was low in this pretreated patient population, since only 
4 patients had stable disease as best observed response.33 
In another phase I study, the combination of paclitaxel and 
bortezomib revealed no response rates.34 Another phase I 
study was carried out to evaluate the combination between 
5-fluorouracil (5-FU) 500 mg/m2 and leucovorin (LV) 
20 mg/m2 with starting dose of bortezomib 0.5 mg/ m2 twice 
weekly for 4 weeks, with 2 weeks rest. One partial response, 
8 stable disease, and 10 progressive disease were achieved 
in 19 patients.35 Another phase I clinical trial evaluated the 
safety and biologic effects of bortezomib and irinotecan 
coadministered in 51 patients. The MTD for the combina-
tion regimen was bortezomib 1.3 mg/m2 twice a week and 
irinotecan 125 mg/m2 on days 1, 8, followed by a 1-week 
rest.36 In another study, escalating doses of bortezomib 
were administered along with standard FOLFOX-4 doses, 
in order to evaluate the DLT, toxicity profile, and activity 
of the combination. Among 13 evaluable patients, 5 had 
a partial response, 5 had stable disease, and 3 progressed. 
Two patients are long-term survivors after a combined 
chemosurgical approach.37
Findings from preclinical studies38 prompted a phase I 
trial to determine the MTD of escalating doses of gemcitabine 
(1000 mg/m2 given once a week for 2 weeks) with bortezomib 
(1.0 mg/m2 given twice a week) every 21 days, in 31 patients 
with advanced solid tumors. This combination was well 
tolerated and a partial response was observed in a patient 
with advanced nonsmall-cell lung cancer (NSCLC), who 
had been pretreated with gemcitabine.39 In another phase I 
study, a combination of bortezomib, gemcitabine, and car-
boplatin induced 4 partial responses and 5 stable diseases in 
16 patients with advanced NSCLC.40
In addition to these studies, the administration of gem-
citabine via fixed-dose rate (FDR) infusion at 10 mg/m2/min 
has been shown to increase accumulation of the active 
phosphorylated metabolite of the drug. Recently, a phase I 
trial was set out to determine the safety, toxicity, and MTD 
of FDR gemcitabine with bortezomib in advanced solid 
tumors refractory to standard therapy. One partial response 
lasting 12 months was observed in breast cancer, and 6 stable 
disease were observed in 29 patients. The combination of 
FDR gemcitabine with bortezomib may warrant further 
studies in advanced breast, lung, ovarianm, and pancreatic 
cancer patients.41
A marked effect of escalating dose of bortezomib 
administered twice weekly for 2 weeks every 21 days in 
combination with a fixed dose of carboplatin (AUC = 5) 
was assessed in 15 patients with advanced ovarian cancer 
who had received upfront chemotherapy and up to 2 prior 
chemotherapy regimens for recurrent disease. The overall 
response rate to this combination was 47%, with 2 complete 
responses and 5 partial responses, including 1 complete 
response in a patient with platinum-resistant disease.42 
A Gynecologic Oncology Group phase II trial of single-
agent bortezomib in recurrent ovarian cancer is currently 
ongoing. Kubicek and co-workers have recently presented 
the preliminary results of a phase I trial of bortezomib, 
cisplatin, and radiotherapy for advanced head and neck 
cancer. The combination proved feasible; main toxicity was 
trombocytopenia; no clinical relevant peripheral neuropathy 
occurred; and most of the other observed toxicities were 
clearly attributable to cisplatin and radiation therapy.43 
The final paper is awaited with full details on safety and 
activity.
Phase I combination studies with bortezomib are sum-
marized in Tables 2 and 3.
Phase ii studies
A large number of phase II studies of single-agent 
bortezomib have been carried out or are currently underway. 
Phase II trials of bortezomib as single agents in patients 
with melanoma,44 recurrent or metastatic sarcomas,45 
neuroendocrine tumors,46 colorectal cancer,47 advanced 
renal cancer,48,49 and advanced breast cancer50,51 revealed 
no significant response rates.
Bortezomib was safe, the most significant clinical adverse 
event being a peripheral sensory neuropathy. Phase II studies 
of single agent bortezomib are summarized in Table 4.
A randomized phase II study was conducted in 87 patients 
with metastatic pancreatic cancer, who were randomized 
to receive bortezomib alone (1.5 mg/m2 twice weekly for 
2 weeks every 3 weeks) or a combination of bortezomib 
(1.0 mg/m2 twice weekly for 2 weeks every 3 weeks) plus 
gemcitabine (1000 mg/m2 on days 1, 8 every 3 weeks). The 
response rate was 0% in the arm with bortezomib alone, 
with median survival of 2.5 months and median time to 
progression of 1.2 months. Four patients achieved a partial 
response in the combination arm, but the benefit obtained 
with bortezomib alone or in combination with gemcitabine 
was low.52OncoTargets and Therapy 2009:2 175
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Fanucchi et al investigated the safety and efficacy of 
bortezomib monotherapy (arm A) compared with the com-
bination of bortezomib and docetaxel (arm B) as second-line 
therapy in 155 patients with locally advanced and metastatic 
NSCLC. Overall response rate was 8% in arm A and 9% 
in arm B. Time to response was 36 to 83 days in arm A, 
5 of 6 patients responding within 40 days, and 38 to 99 days in 
arm B, 2 of 7 patients responding within 41 days.53 Bortezomib 
plus docetaxel seemed to demonstrate modest benefit com-
pared with bortezomib monotherapy. Phase II combination 
studies of bortezomib are summarized in Table 5.
Conclusion and future perspectives
The 26S proteasome acts as a housekeeper to eliminate 
damaged or misfolded proteins. In addition, many 
regulatory proteins governing the cell cycle, transcription 
factor activation, apoptosis, and cell trafficking are the 
substrates for proteasome-mediated degradation. Five 
years after entering clinical trials, bortezomib has demon-
strated efficacy for the treatment of patients with recurrent 
and refractory multiple myeloma. The clinical results in 
multiple myeloma provide proof of concept for proteasome 
inhibition as an anticancer therapy, and the role of bort-
ezomib in other types of cancer therapy is undergoing 
active investigation. In contrast to the results of myeloma, 
the treatment of solid tumors with either single-agent 
bortezomib or bortezomib in combination with conven-
tional chemotherapy agents has not yet yielded significant 
improvements in treatment response. Probably, a more 
extensive investigation of the survival signals induced by 
proteasome inhibition may offer further insight into the 
poor responses of solid malignancies.
The dysregulation of a variety of pathways, such 
as NF-κB, epidermal growth factor receptor (EGFR), 
Table 3 Phase I disease specific combination studies of bortezomib
Patient 
population
Advanced NSCLC Advanced 
ovarian tumors
Advanced head and 
neck cancer
Advanced colorectal 
cancer
Number of 
patients
16 15 17 13
Schedule Starting dose of 1.0 mg/m2 
iv on days 1, 4, 8, 11 + 
gemcitabine 800 mg/m2 
on days 1, 8 + CBDCA AUC 
5 on day 1 q3 weeks
Starting dose of 
0.75 mg/m2 iv on 
days 1, 4, 8, 11 + 
CBDCA AUC 5 on 
day 1 q3 weeks
Starting dose of 
0.7 mg/m2 iv on days 1, 4, 
8, 11 + CDDP 30 mg/m2 
on day 1 q3 weeks
Starting dose of 
1.03 mg/m2 iv on days 1, 8, 
15 + FOLFOX-4 q2 weeks
Best response 
obtained
4 Pr  
5 SD
2 Cr  
5 Pr
Nr 5 Pr  
5 SD
Toxicity 
observed
Myelosuppression Diarrhea Thrombocytopenia Myelosuppression  
and diarrhea
Abbreviations: NSLC, nonsmall-cell lung cancer; Pr, partial response; SD, stable disease; Nr, not reported; CBDCA, carboplatin; CDDP, cisplatin.
Table 2 Phase i combination studies of bortezomib in advanced solid tumors
Number 
of patients
21 14 25 51 31 29
Schedule Starting dose 
of 0.5 mg/m2 iv 
twice weekly + 
5-FU 500 mg/m2 
+ leucovorin 
20 mg/m2 on 
day 1 q2 weeks
Starting dose 
of 0.8 mg/m2 iv 
on days 2, 5, 9, 
12 + docetaxel 
25 mg/m2 
on days 1, 8 
q3 weeks
Starting dose 
of 0.6 mg/m2 iv 
on days 2, 5, 9, 
12 + paclitaxel 
80 mg/m2 
on days 1, 8 
q3 weeks
Starting dose 
of 1.3 mg/m2 iv 
twice a week 
+ irinotecan 
125 mg/m2 
on days 1, 8 
q3 weeks
Starting dose 
of 1.0 mg/m2 iv 
twice a week 
+ gemcitabine 
1000 mg/m2 on 
days 1, 8 q3 weeks
Starting dose of 
1.0 mg/m2 iv on 
days 1, 4, 8, 11 + 
FDr gemcitabine 
750, 1000, 
1250 mg/m2 on 
days 1, 8 q3 weeks
Best response 
obtained
1 Pr  
8 SD
4 SD 1 Pr 10 SD 1 Pr  
7 SD
1 Pr  
6 SD
Toxicity observed Abdominal pain 
and diarrhea
Hematologic Neurotoxicity 
and fatigue
Diarrhea, 
nausea and 
vomiting
Abdominal pain and 
hematologic
Neutropenia and 
thrombocytopenia
Abbreviations: FDR, fixed dose rate; PR, partial response; SD, stable disease; 5FU, 5-fluorouracil.OncoTargets and Therapy 2009:2 176
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and Ras/PI3K/Akt, is very common in solid tumors. 
It is known that bortezomib also interferes with the p44/42 
mitogen-activated protein kinase (MAPK), a downstream 
effector of EGFR pathway that communicates proliferative 
signals, and induces accumulation of cyclin-dependent kinase 
inhibitors p21Cip1 and p27Kip1.54 Signaling by the EGFR fam-
ily occurs through several downstream pathways to promote 
cell proliferation and inhibit apoptosis,55,56 suggesting that 
EGFR itself might be subjected to ubiquitination and sub-
sequent proteolityc breakdown, and that this process might 
be affected by proteasome inhibition. On the basis of this 
assumption, a preclinical study was carried out to evaluate 
the effect of proteasome inhibitor on EGFR survival signal-
ing in pancreatic cancer cells.57 Intriguingly, the addition 
of EGFR inhibition only enhanced proteasome inhibi-
tor effects in vivo but not in vitro, suggesting that some 
other paracrine response may be involved in the effects of 
EGFR inhibition in vivo. An and Rettig have described the 
importance of the sequence of drug administration when 
bortezomib is used in combination with an EGFR tyrosine 
kinase inhibitor in renal carcinoma cells.58 They concluded 
that pre-treatment of renal carcinoma cells with the EGFR 
tyrosine kinase inhibitor prior to bortezomib was cytotoxic, 
whereas an antagonist interaction resulted with the reverse 
schedule. The authors also postulated that the diminished 
AKT and NF-κB, inhibition observed when renal carcinoma 
cells were pretreated with bortezomib, might result from 
decreased degradation of signaling proteins that function 
to converge on the EGFR/PI3K/AKT/NF-κB pathway, 
although direct evidence to support or refute this hypothesis 
does not yet exist.
In summary, these findings show that proteasome 
inhibitor treatment activates several mitogenic signaling 
pathways that blunt the full potential of the apoptotic 
response to proteasome inhibitor treatment. As an alternative 
or addition to EGFR inhibition, selective inhibition of these 
downstream mitogenic signaling pathways may increase 
the apoptotic response to proteasome inhibition and further 
overcome the drug resistance mechanisms in solid tumors. 
These preclinical studies might identify new drug combina-
tions to enter clinical trials.
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Table 5 Phase ii combination studies of bortezomib
Patient 
population
Metastatic colorectal 
cancer
Metastatic pancreatic 
carcinoma
Pretreated NSCLC
Number of 
patients
68 87 155
Schedule Arm 1: 1.5 mg/m2 on 
days 1, 4, 8, 11 q21 days 
Arm 2: 1.3 mg/m2 on days 1, 
4, 8, 11 + CPT 11 125 mg/m2 
on day 1 q21 days
Arm 1: 1.5 mg/m2 
on days 1, 4, 8, 11 
q21 days Arm 2: 1.3 mg/m2 on 
days 1, 4, 8, 11 + gemcitabine 
1000 mg/m2 on day 1 q21 days
Arm 1: 1.5 mg/m2 on days 1, 4, 8, 
11 q21 days Arm 2: 1.3 mg/m2 on 
days 1,4,8,11 + docetaxel 75 mg/m2 
on day 1 q21
response rates % NA 10% rr 42% rr
Toxicity observed Hematologic, neurotoxicity 
and fatigue
Abdominal pain, fatigue and 
thrombocytopenia
Neutropenia, neurotoxicity and 
fatigue
Abbreviations: rr, response rate; CPT, irinotecan.
Table 4 Phase ii single agent studies of bortezomib
Patient 
population
Metastatic 
melanoma
Recurrent/metastatic 
soft tissue sarcoma
Metastatic 
neuroendocrine 
tumors
Metastatic 
colorectal 
cancer
Advanced 
renal tumors
Metastatic 
breast cancer
Number of 
patients
27 25 16 19 60 24
Best response 
obtained
6 SD 1 Pr 11 SD 3 SD 5 Pr 14 SD 1 SD
Toxicity 
observed
Neurotoxicity, 
fatigue and 
thrombocytopenia
Neurotoxicity, myalgia 
and fatigue
Neurotoxicity, 
diarrea and vomiting
Neurotoxicity 
and myalgia
Neurotoxicity Thrombocytopenia 
and fatigue
Abbreviations: Pr, partial response; SD, stable disease.OncoTargets and Therapy 2009:2 177
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